Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments

Vaginal Atrophy Clinical Trial

Official title:

Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02704741
• Other study ID #: DHF19731
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 2015
• Est. completion date: September 2019

Study information

• Verified date: June 2018
• Source: Syneron Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.

Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).

Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic.

Description:

This study is a Prospective clinical study to demonstrate the CO2RE laser device for safety and efficacy for Vaginal Atrophy.

Up to a total of 60 healthy candidates, seeking vaginal treatment from the participating investigator will be enrolled at a participating study site. Subjects will receive three (3) CO2RE treatments.

Each subject will be followed for additional 5 post treatment visits (FU visits) that will be conducted at:

• One week post first treatment - 1wk FU ± 2 days (Safety).

• 1 month post last treatment - 1m FU ± 2 weeks (efficacy & Safety).

• 3 months post last treatment - 3m FU ± 2 weeks (efficacy & Safety).

• 6 months post last treatment - 6m FU ± 2 weeks (efficacy & Safety).

• 12 months post last treatment - 12m FU ± 2 weeks (efficacy & Safety).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 61
• Est. completion date: September 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

1. Subjects seeking treatment of Vaginal Atrophy in the vagina area (External - vestibule and introitus; Internal - Vaginal canal)

2. Healthy female subjects age greater than or equal to 35 years of age who are post menopausal for at least one year, for any reason whether surgical , chemical or natural.

3. Absence of menstruation for at least 12 months

4. Not responding to or satisfied with previous local estrogen therapy

5. Desire to maintain sexual activity

6. Informed consent process completed and subject signed consent

7. Willing to receive the proposed CO2RE treatment and follow-up protocol

8. Post-menopausal or surgically sterilized.

9. Normal cell cytology (PAP smear)

10. Negative urinalysis and a normal vaginal canal (no evidence of dysplasia and occult or active infection)

11. The external vaginal area (vestibule and introitus) free of injuries and bleeding

12. Subject experienced sexual activity at least once a month

Exclusion Criteria:

1. Subject had surgery or any other procedure for Vaginal Tightening in the last 12 months

2. Use of hormone replacement therapy, either systemic or local within the last 6 months prior to study

3. Lubricants or any localized preparation in the 30 days prior to enrollment

4. Patient with history of herpes.

5. Acute or recurrent urinary tract infection (UTI) or genital infection (e.g. herpes, candida)

6. Active malignancy or history of malignancy in the past 5 years

7. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator

8. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the treatment, or healing process)

9. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion)

10. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications

11. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen

12. History of significant lymphatic drainage problems

13. History of cancer which required lymph node biopsy or dissection

14. Suffering from significant conditions in the treated areas or inflammatory conditions, including, but not limited to, open lacerations or abrasions of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course

15. History of keloid scarring, abnormal wound healing and / or prone to bruising

16. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders

17. Use of isotretinoin (Accutane®) within 6 months of treatment or during the study

18. Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study

19. Dysplastic nevi in the area to be treated

20. Participation in a study of another device or drug within 6 month prior to enrollment or during this study, if treatments of vagina were involved

21. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

22. Prolapse staged >_ II, according to the pelvic organ prolapse quantification (ICS-POP-Q) system

23. Previously undergone pelvic reconstructive surgery

Related Conditions & MeSH terms

• Atrophy
• Vaginal Atrophy

Intervention

Device:
• CO2RE
The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin

Locations

Country	Name	City	State
United States	FamWell.MD	Jacksonville	Florida
United States	6400 Dutchmans Pkwy Ste 335 Louisville, KY 40205 US	Louisville	Kentucky
United States	Dermatology and Laser Surgery Center of New York	New York	New York
United States	Syneron-Candela Institute for Excellence	Wayland	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Syneron Medical

Country where clinical trial is conducted

United States, 

References & Publications (1)

Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, Ferrero S, Origoni M, Candiani M, Leone Roberti Maggiore U. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric. 2015 Apr;18(2):219-25. doi: 10.3109/13697137.2014.975197. Epub 2014 Dec 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Vulvovaginal Symptom Questionnaire	Vulvovaginal Symptom Questionnaire will be used to evaluate improvement of vulvovaginal atrophy symptoms.	Baseline, 1 , 2 , 3, 5, 8, and 14 months
Secondary	Number of participants with adverse events	Number, severity and duration of adverse events following CO2 treatment	throughout study duration, day 0 up to 17 months
Secondary	Vaginal Health Index Improvement	Evaluation of vaginal wall conditions such as pH, elasticity, bleeding signs, secretion type and consistency and hydration.	Baseline, 1 , 2 , 3, 5, 8, and 14 months
Secondary	Change from Baseline in Female Sex Function Index	Female Sex Function Index will be used to evaluate improvement of vulvovaginal atrophy symptoms	Baseline, 1 , 2 , 3, 5, 8, and 14 months
Secondary	Satisfaction questionnaire	A questionnaire will be used to evaluate satisfaction with treatment outcome	2 weeks and 1 , 2 , 3, 5, 8, and 14 months
Secondary	Visual analog score for pain	Patients will complete a visual analog scale to report pain level associated with treatment	day 0, 4 weeks, 8 weeks